Splice it up: Atypical transcripts to boost leukemia immunotherapy.

Abstract excerpt

Neoantigens are prime targets for cancer immunotherapy, but their identification in low mutational burden malignancies remains challenging. In this issue of Immunity, Ehx et al. show that atypical transcripts, and particularly retained introns, expand the spectrum of leukemia immunotherapy targets.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antigens, Neoplasm
• Share to Immunotherapy
• Share to Leukemia